Midomafetamine is under clinical development by AWAKN Life Sciences and currently in Phase II for Alcohol Dependence. According to GlobalData, Phase II drugs for Alcohol Dependence does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Midomafetamine LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Midomafetamine overview

Midomafetamine is under development for the treatment of alcohol use disorder. The drug candidate acts by targeting monoamine oxidase (MAO), sodium dependent dopamine transporter (SLC6A3) and sodium dependent noradrenaline transporter (SLC6A2). It is administered through oral route in the form of tablet. It is being developed based on orally disintegrating tablet (ODT) technology.

AWAKN Life Sciences overview

AWAKN Life Sciences (AWAKN) is a provider of evidence-based psychedelic assisted psychotherapy solutions to heal mental health conditions. AWAKN is headquartered in Toronto, Ontario, Canada.

For a complete picture of Midomafetamine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.